FASLG and neoplasm: To assess the role of IL-9 in the antitumor effects of FasL-TH9, we intravenously or subcutaneously challenged Il9r−/− mice with B16F10-OVA tumor cells and found that neither FasL-TH9 nor cTH9 enhanced antitumor immunity (Fig. 6i–k).